Novartis to Buy Multiple Sclerosis Drug From Glaxo
The experimental drug ofatumumab would bolster the Swiss pharmaceutical company’s portfolio of multiple sclerosis treatments.
Continue Reading
The experimental drug ofatumumab would bolster the Swiss pharmaceutical company’s portfolio of multiple sclerosis treatments.
Continue Reading
Join the Discussion